Skip to main content
. 2010 Jun 15;18(8):1430–1439. doi: 10.1038/mt.2010.98

Figure 2.

Figure 2

Turning the immune response against the oncolytic virus into a beneficial one. (a) Timeline for combination treatment with Ad-hDCT and VSV-hDCT. (b) Blood was collected 6 days after VSV treatment and intracellular staining for IFN-γ in response to the dominant epitopes for DCT and the VSV nucleocapsid was performed. (c) Pooled survival data from three independent experiments. Mice were treated with empty Ad vector (Ad-BHG), Ad-hDCT alone, Ad-hDCT followed by VSV-GFP or Ad-hDCT followed by VSV-hDCT (n = 19, n = 18, n = 21, and n = 15, respectively). Median survival: 15, 30, 32, and 54 days, respectively. Ad, adenovirus; DCT, dopachrome tautomerase; hDCT, human DCT; PBS, phosphate-buffered saline; i.c., intracranial; IFN, interferon; i.v., intravenous; VSV, vesicular stomatitis virus.